Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Venous Thromboembolism | 21 | 2024 | 1881 | 3.970 |
Why?
|
Antithrombin III Deficiency | 4 | 2024 | 28 | 2.790 |
Why?
|
Antithrombin III | 6 | 2024 | 128 | 2.610 |
Why?
|
Thrombophilia | 5 | 2024 | 306 | 2.430 |
Why?
|
Hemophilia A | 6 | 2022 | 359 | 2.200 |
Why?
|
Anticoagulants | 19 | 2024 | 4835 | 1.790 |
Why?
|
Hemostasis | 4 | 2023 | 470 | 1.490 |
Why?
|
Heparin | 4 | 2021 | 1636 | 1.460 |
Why?
|
Hemostatics | 3 | 2022 | 247 | 1.420 |
Why?
|
Frameshift Mutation | 2 | 2024 | 393 | 1.410 |
Why?
|
Upper Extremity Deep Vein Thrombosis | 2 | 2021 | 26 | 1.410 |
Why?
|
Fibrinogens, Abnormal | 2 | 2020 | 10 | 1.400 |
Why?
|
Afibrinogenemia | 2 | 2020 | 17 | 1.400 |
Why?
|
Postthrombotic Syndrome | 3 | 2014 | 28 | 1.320 |
Why?
|
Anemia, Sickle Cell | 5 | 2022 | 1065 | 1.300 |
Why?
|
Drug Monitoring | 4 | 2021 | 964 | 1.240 |
Why?
|
Venous Thrombosis | 8 | 2020 | 1317 | 1.220 |
Why?
|
Blood Coagulation Disorders | 2 | 2023 | 350 | 1.190 |
Why?
|
Heterozygote | 2 | 2024 | 2792 | 0.960 |
Why?
|
Hemorrhage | 8 | 2021 | 3456 | 0.960 |
Why?
|
Thrombolytic Therapy | 4 | 2021 | 2058 | 0.870 |
Why?
|
Hemophilia B | 2 | 2016 | 83 | 0.850 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2022 | 87 | 0.810 |
Why?
|
Thrombosis | 4 | 2023 | 2954 | 0.780 |
Why?
|
Blood Coagulation | 5 | 2022 | 1163 | 0.760 |
Why?
|
22q11 Deletion Syndrome | 1 | 2021 | 18 | 0.750 |
Why?
|
Partial Thromboplastin Time | 2 | 2019 | 204 | 0.700 |
Why?
|
Thoracic Outlet Syndrome | 1 | 2021 | 97 | 0.680 |
Why?
|
Databases, Factual | 4 | 2024 | 8081 | 0.670 |
Why?
|
Catheterization, Swan-Ganz | 1 | 2019 | 86 | 0.660 |
Why?
|
Adolescent | 37 | 2024 | 89163 | 0.650 |
Why?
|
Cytapheresis | 1 | 2018 | 8 | 0.650 |
Why?
|
Child | 36 | 2024 | 80856 | 0.600 |
Why?
|
Klinefelter Syndrome | 1 | 2018 | 48 | 0.600 |
Why?
|
Vena Cava, Inferior | 2 | 2018 | 463 | 0.580 |
Why?
|
Child, Preschool | 24 | 2024 | 42620 | 0.580 |
Why?
|
Pulmonary Embolism | 4 | 2021 | 2591 | 0.580 |
Why?
|
Factor Xa | 2 | 2019 | 166 | 0.580 |
Why?
|
Mesenteric Arteries | 1 | 2018 | 178 | 0.570 |
Why?
|
Exercise Therapy | 2 | 2022 | 941 | 0.570 |
Why?
|
Popliteal Artery | 1 | 2019 | 313 | 0.570 |
Why?
|
Nomograms | 1 | 2019 | 236 | 0.560 |
Why?
|
Fibrinogen | 1 | 2020 | 893 | 0.550 |
Why?
|
Thrombocytopenia | 2 | 2016 | 1183 | 0.550 |
Why?
|
von Willebrand Disease, Type 3 | 2 | 2013 | 5 | 0.540 |
Why?
|
von Willebrand Disease, Type 2 | 1 | 2016 | 7 | 0.540 |
Why?
|
Valproic Acid | 1 | 2019 | 443 | 0.530 |
Why?
|
Arterial Occlusive Diseases | 1 | 2019 | 751 | 0.500 |
Why?
|
Infant | 21 | 2024 | 36496 | 0.490 |
Why?
|
Angioplasty, Balloon | 1 | 2018 | 592 | 0.480 |
Why?
|
Antithrombin Proteins | 1 | 2014 | 10 | 0.470 |
Why?
|
Decision Support Systems, Clinical | 1 | 2024 | 1176 | 0.460 |
Why?
|
Lower Extremity | 2 | 2019 | 1214 | 0.460 |
Why?
|
Thromboembolism | 1 | 2021 | 1005 | 0.460 |
Why?
|
Fibrinolytic Agents | 2 | 2023 | 2082 | 0.450 |
Why?
|
Point Mutation | 1 | 2019 | 1596 | 0.450 |
Why?
|
Blood Coagulation Factors | 1 | 2016 | 366 | 0.440 |
Why?
|
Decompression, Surgical | 1 | 2018 | 612 | 0.430 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 928 | 0.400 |
Why?
|
von Willebrand Diseases | 1 | 2013 | 134 | 0.390 |
Why?
|
Orthopedic Procedures | 1 | 2021 | 1280 | 0.380 |
Why?
|
Dermatofibrosarcoma | 1 | 2011 | 48 | 0.380 |
Why?
|
Sinus Thrombosis, Intracranial | 1 | 2012 | 110 | 0.380 |
Why?
|
Factor VIII | 4 | 2022 | 349 | 0.380 |
Why?
|
Young Adult | 18 | 2024 | 60038 | 0.360 |
Why?
|
Body Weight | 2 | 2021 | 4630 | 0.360 |
Why?
|
Ischemia | 1 | 2019 | 1900 | 0.360 |
Why?
|
Histiocytic Sarcoma | 1 | 2011 | 40 | 0.360 |
Why?
|
Sports | 2 | 2016 | 709 | 0.360 |
Why?
|
Infant, Newborn | 11 | 2022 | 26394 | 0.350 |
Why?
|
Genes, p16 | 1 | 2011 | 160 | 0.350 |
Why?
|
Humans | 65 | 2024 | 768369 | 0.350 |
Why?
|
Male | 41 | 2024 | 364761 | 0.350 |
Why?
|
Acute Chest Syndrome | 1 | 2010 | 32 | 0.340 |
Why?
|
Anticonvulsants | 1 | 2019 | 1923 | 0.320 |
Why?
|
Brain Ischemia | 1 | 2022 | 3038 | 0.320 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 230 | 0.320 |
Why?
|
Wilms Tumor | 1 | 2011 | 378 | 0.310 |
Why?
|
Prednisone | 2 | 2011 | 1568 | 0.310 |
Why?
|
Ribs | 2 | 2021 | 261 | 0.310 |
Why?
|
Aneurysm, False | 1 | 2011 | 264 | 0.300 |
Why?
|
Executive Function | 1 | 2017 | 1402 | 0.300 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 695 | 0.300 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2011 | 555 | 0.290 |
Why?
|
Stroke | 2 | 2022 | 9790 | 0.290 |
Why?
|
Female | 35 | 2024 | 396926 | 0.290 |
Why?
|
von Willebrand Factor | 3 | 2016 | 679 | 0.280 |
Why?
|
Lymphoma, Follicular | 1 | 2011 | 460 | 0.270 |
Why?
|
Genetic Association Studies | 1 | 2016 | 2742 | 0.270 |
Why?
|
Pelvis | 1 | 2011 | 737 | 0.270 |
Why?
|
Risk Factors | 16 | 2024 | 74915 | 0.260 |
Why?
|
Retrospective Studies | 16 | 2024 | 81835 | 0.260 |
Why?
|
Blood Coagulation Tests | 2 | 2017 | 271 | 0.250 |
Why?
|
Mutation | 5 | 2023 | 30235 | 0.250 |
Why?
|
Hospitalization | 2 | 2024 | 10845 | 0.240 |
Why?
|
Follow-Up Studies | 6 | 2024 | 39429 | 0.230 |
Why?
|
Drug Dosage Calculations | 2 | 2021 | 117 | 0.220 |
Why?
|
Quality of Life | 2 | 2016 | 13497 | 0.210 |
Why?
|
Adult | 19 | 2023 | 223528 | 0.210 |
Why?
|
Body Mass Index | 1 | 2021 | 13030 | 0.210 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1062 | 0.210 |
Why?
|
Cognition Disorders | 1 | 2017 | 3984 | 0.210 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2017 | 5708 | 0.190 |
Why?
|
Embolization, Therapeutic | 1 | 2011 | 1435 | 0.180 |
Why?
|
Prognosis | 4 | 2024 | 30031 | 0.180 |
Why?
|
Phenotype | 4 | 2023 | 16712 | 0.180 |
Why?
|
Glucocorticoids | 1 | 2010 | 2170 | 0.180 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15965 | 0.170 |
Why?
|
Antithrombins | 1 | 2023 | 294 | 0.170 |
Why?
|
Acute Generalized Exanthematous Pustulosis | 1 | 2009 | 15 | 0.170 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2009 | 33 | 0.170 |
Why?
|
Exercise | 1 | 2016 | 5940 | 0.160 |
Why?
|
Half-Life | 2 | 2019 | 650 | 0.160 |
Why?
|
Obesity | 1 | 2021 | 13065 | 0.150 |
Why?
|
Cohort Studies | 5 | 2021 | 41782 | 0.150 |
Why?
|
Cellulitis | 1 | 2009 | 209 | 0.140 |
Why?
|
Phlebography | 1 | 2018 | 326 | 0.140 |
Why?
|
Genotype | 3 | 2018 | 13045 | 0.140 |
Why?
|
Ultrasonography, Doppler | 1 | 2018 | 463 | 0.130 |
Why?
|
Drug Eruptions | 1 | 2009 | 335 | 0.130 |
Why?
|
Hemarthrosis | 1 | 2016 | 39 | 0.130 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 620 | 0.130 |
Why?
|
Skin Neoplasms | 2 | 2014 | 5891 | 0.130 |
Why?
|
Diagnosis, Differential | 3 | 2018 | 13025 | 0.130 |
Why?
|
Patient Readmission | 1 | 2010 | 3308 | 0.130 |
Why?
|
Edetic Acid | 1 | 2016 | 278 | 0.130 |
Why?
|
Kidney Neoplasms | 1 | 2011 | 4299 | 0.120 |
Why?
|
Nail Diseases | 1 | 2014 | 55 | 0.120 |
Why?
|
Pilot Projects | 2 | 2018 | 8730 | 0.110 |
Why?
|
Thrombelastography | 1 | 2016 | 190 | 0.110 |
Why?
|
Pandemics | 2 | 2024 | 8751 | 0.110 |
Why?
|
Urogenital Neoplasms | 1 | 2014 | 133 | 0.110 |
Why?
|
Platelet Count | 1 | 2016 | 786 | 0.110 |
Why?
|
Genes, X-Linked | 1 | 2013 | 128 | 0.100 |
Why?
|
Eye Neoplasms | 1 | 2014 | 307 | 0.100 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 26348 | 0.100 |
Why?
|
Immunoassay | 1 | 2016 | 746 | 0.100 |
Why?
|
Inpatients | 1 | 2024 | 2561 | 0.100 |
Why?
|
Survival Rate | 2 | 2020 | 12875 | 0.100 |
Why?
|
Treatment Outcome | 7 | 2021 | 65408 | 0.100 |
Why?
|
Mucous Membrane | 1 | 2014 | 660 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 11844 | 0.090 |
Why?
|
Leukemia, Biphenotypic, Acute | 1 | 2010 | 32 | 0.090 |
Why?
|
Vascular Surgical Procedures | 1 | 2019 | 1509 | 0.090 |
Why?
|
Leukemia, T-Cell | 1 | 2010 | 101 | 0.090 |
Why?
|
Prevalence | 2 | 2018 | 15879 | 0.090 |
Why?
|
Genes, Recessive | 1 | 2013 | 625 | 0.090 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 3074 | 0.090 |
Why?
|
Genes, Dominant | 1 | 2013 | 856 | 0.090 |
Why?
|
Binding Sites | 1 | 2019 | 6029 | 0.090 |
Why?
|
Enzyme Activation | 1 | 2016 | 3594 | 0.090 |
Why?
|
Family | 1 | 2021 | 3208 | 0.090 |
Why?
|
Furans | 1 | 2011 | 201 | 0.080 |
Why?
|
Hospitals | 1 | 2022 | 3906 | 0.080 |
Why?
|
Prospective Studies | 3 | 2023 | 54913 | 0.080 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2010 | 534 | 0.080 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1282 | 0.080 |
Why?
|
Vincristine | 1 | 2011 | 1039 | 0.080 |
Why?
|
Protein Conformation | 1 | 2016 | 3972 | 0.080 |
Why?
|
Jugular Veins | 1 | 2009 | 211 | 0.080 |
Why?
|
Hospitals, Pediatric | 1 | 2017 | 1876 | 0.080 |
Why?
|
Remission Induction | 2 | 2011 | 2408 | 0.080 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2011 | 2525 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2011 | 711 | 0.070 |
Why?
|
Exons | 1 | 2013 | 2392 | 0.070 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 959 | 0.070 |
Why?
|
Thiophenes | 1 | 2011 | 570 | 0.070 |
Why?
|
Logistic Models | 2 | 2018 | 13323 | 0.070 |
Why?
|
Incidence | 3 | 2022 | 21552 | 0.070 |
Why?
|
Pedigree | 1 | 2014 | 4545 | 0.070 |
Why?
|
Calcium | 1 | 2019 | 5793 | 0.060 |
Why?
|
Models, Molecular | 1 | 2016 | 5441 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2021 | 22286 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 36840 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4120 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 10358 | 0.060 |
Why?
|
Recurrence | 1 | 2018 | 8510 | 0.060 |
Why?
|
Cell Separation | 1 | 2011 | 1725 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2011 | 2224 | 0.060 |
Why?
|
Transplantation Conditioning | 1 | 2012 | 1598 | 0.060 |
Why?
|
Hodgkin Disease | 1 | 2012 | 1386 | 0.060 |
Why?
|
Doxorubicin | 1 | 2011 | 2229 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2013 | 2590 | 0.060 |
Why?
|
Physicians | 1 | 2022 | 4615 | 0.060 |
Why?
|
Base Sequence | 1 | 2014 | 12426 | 0.060 |
Why?
|
Age Factors | 2 | 2021 | 18477 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2014 | 18047 | 0.050 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2010 | 1614 | 0.050 |
Why?
|
Survival Analysis | 1 | 2014 | 10127 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2010 | 2431 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7467 | 0.040 |
Why?
|
Embolectomy | 1 | 2021 | 130 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 1 | 2010 | 2819 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 2915 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2011 | 5893 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2010 | 2987 | 0.040 |
Why?
|
Prothrombin Time | 1 | 2019 | 117 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2022 | 15879 | 0.040 |
Why?
|
Cognition | 1 | 2017 | 7062 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 3042 | 0.040 |
Why?
|
North America | 1 | 2022 | 1292 | 0.040 |
Why?
|
Radiology, Interventional | 1 | 2022 | 478 | 0.040 |
Why?
|
Depression | 1 | 2017 | 8235 | 0.030 |
Why?
|
Melanoma | 1 | 2014 | 5740 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2010 | 3623 | 0.030 |
Why?
|
Neutropenia | 1 | 2019 | 892 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3207 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2012 | 13709 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4861 | 0.020 |
Why?
|
Bacteremia | 1 | 2018 | 985 | 0.020 |
Why?
|
Acute Disease | 1 | 2021 | 7245 | 0.020 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2018 | 861 | 0.020 |
Why?
|
Anemia | 1 | 2019 | 1521 | 0.020 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2010 | 348 | 0.020 |
Why?
|
United States | 1 | 2018 | 73120 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 2012 | 8559 | 0.020 |
Why?
|
Gestational Age | 1 | 2018 | 3615 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2012 | 499 | 0.020 |
Why?
|
Catheters, Indwelling | 1 | 2009 | 436 | 0.020 |
Why?
|
Middle Aged | 1 | 2021 | 223406 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2010 | 1496 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 2010 | 1395 | 0.010 |
Why?
|
Length of Stay | 1 | 2018 | 6521 | 0.010 |
Why?
|
Sex Factors | 1 | 2018 | 10647 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4582 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 2010 | 2702 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2012 | 6856 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6537 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 24310 | 0.010 |
Why?
|
Ultrasonography | 1 | 2009 | 5994 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2010 | 12813 | 0.010 |
Why?
|